Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A. Rich(Guardant (United States)), Oliver Gautschi(University of Bern), Thomas E. Stinchcombe(Duke Medical Center), Wade T. Iams(Centerstone), Stephen R. Fairclough(University of California, Berkeley), Robert C. Doebele(University of Colorado Anschutz Medical Campus), Michael S. Oh(Northwestern University), Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Young Kwang Chae(Johns Hopkins University), Jonathan W. Riess(Comprehensive Blood & Cancer Center), Jennifer Yen(Guardant (United States)), David R. Trevarthen(University of Colorado Cancer Center), Victoria M. Raymond(Guardant (United States)), Richard B. Lanman(Guardant (United States))
Cited by 91
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k